Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial

The new obesity treatment demonstrated up to 13% weight loss in 12 weeks, potentially outperforming existing injections like Wegovy.

Amycretin, a once-daily tablet, mimics the action of two appetite-regulating hormones, amylin and GLP-1.
In a Phase 1 trial, participants lost an average of 10.4% to 13.1% of their body weight, significantly higher than the placebo group's 1.1%.
The study included 124 overweight or obese participants without diabetes, focusing solely on weight loss effects.
Common side effects were mild to moderate gastrointestinal issues, with better tolerability achieved through stepwise dose escalation.
Further large-scale and long-term studies are needed before amycretin can be considered for regulatory approval.